Testing a new PET scan tracer for cancer diagnosis
Part of Cancer clinical trials.
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have a strong suspicion of cancer (based on tests or symptoms).
- You can understand the study and sign a consent form.
- You do not have severe heart or kidney problems, or trouble being in closed spaces.
- You are not allergic to alcohol and have not taken certain antibiotics (like penicillin) in the past week.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
This Phase 1 study tests a special imaging scan (using FAP-2286) to see solid tumors in people who have already been diagnosed. It may help doctors better detect where cancer is in the body and how to plan treatment.
This trial tests a new PET/CT scan that uses a special tracer (68Ga-FAPI-Biotin) to help detect and see various solid tumors. It may provide more detailed images to guide treatment decisions.
This study tests a new PET/CT imaging agent (gallium-68 FFD) to see how well it works in both healthy volunteers and people with solid tumors. It could help doctors find or monitor cancer more accurately.
This trial tests a new radioactive tracer called 68Ga-SFB6-ZN01 for PET/CT scans in people with suspected or confirmed solid tumors. It aims to see if this tracer can help find cancer or detect recurrence after treatment.
This trial tests a special PET scan using a tracer that attaches to certain markers (PSMA and FAP) found on some cancers. It aims to help doctors see where the cancer is, possibly leading to better treatment decisions.
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.